Aduro BioTech Inc (NASDAQ:ADRO) COO Gregory W. Schafer sold 25,811 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $12.17, for a total value of $314,119.87. Following the completion of the sale, the chief operating officer now directly owns 133,879 shares of the company’s stock, valued at $1,629,307.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Aduro BioTech Inc (NASDAQ ADRO) traded down 1.22% during trading on Wednesday, reaching $12.15. The company’s stock had a trading volume of 354,202 shares. Aduro BioTech Inc has a 12 month low of $8.75 and a 12 month high of $16.18. The stock’s 50 day moving average is $12.28 and its 200 day moving average is $10.96. The company’s market cap is $895.16 million.
Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. Aduro BioTech had a negative return on equity of 31.97% and a negative net margin of 327.87%. The business had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $3.98 million. During the same quarter last year, the business posted $0.03 EPS. The company’s quarterly revenue was down 84.9% on a year-over-year basis. On average, equities analysts expect that Aduro BioTech Inc will post ($1.37) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2795981/aduro-biotech-inc-adro-coo-gregory-w-schafer-sells-25811-shares.html.
A number of analysts have recently issued reports on the company. HC Wainwright assumed coverage on Aduro BioTech in a research report on Monday, May 1st. They issued a “buy” rating and a $18.00 price objective for the company. BidaskClub raised Aduro BioTech from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Cowen and Company assumed coverage on Aduro BioTech in a research report on Tuesday, July 18th. They issued an “outperform” rating for the company. Zacks Investment Research cut Aduro BioTech from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 2nd. Finally, Canaccord Genuity set a $30.00 price target on Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $19.00.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its position in Aduro BioTech by 9.1% in the first quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock worth $101,571,000 after buying an additional 791,770 shares in the last quarter. Norges Bank purchased a new position in Aduro BioTech during the fourth quarter worth approximately $3,266,000. JPMorgan Chase & Co. boosted its position in Aduro BioTech by 283.7% in the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after buying an additional 275,295 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Aduro BioTech by 330.5% in the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock worth $2,545,000 after buying an additional 181,734 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Aduro BioTech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after buying an additional 160,800 shares in the last quarter. 35.60% of the stock is currently owned by institutional investors and hedge funds.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.